Stockreport

AbbVie prices new rheumatoid arthritis drug at $59,000/yr [Reuters (UK)]

AbbVie Inc.  (ABBV) 
Last abbvie inc. earnings: 5/1 07:43 am Check Earnings Report
US:NYSE Investor Relations: investors.abbvie.com/investor-overview
PDF AbbVie prices new rheumatoid arthritis drug at $59,000/yr - Reuters 3 Min Read (Reuters) - AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year [Read more]